Results 11 to 20 of about 7,348 (201)

Immune-Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report. [PDF]

Clin Case Rep
Timeline of events ABSTRACT Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease. We confirmed immune‐mediated thrombocytopenia (ITP) in one of our patients after the initiation of filgotinib. Whether this was drug‐induced is uncertain.
van der Hoff MJ, El-Morabit F, Löwenberg M.   +2 more
europepmc   +2 more sources

Drug-Induced Intersticial Nephritis. Clinical Case

Acta Medica Lituanica, 2021
5-Aminosalicylic acid (5-ASA) preparations are widely used in the treatment of inflammatory bowel diseases. The most commonly used medicine is mesalamine. Overall, it is a very safe drug with few side effects.
Paulina Tekoriutė, Monika Matuliauskaitė, Laimas Virginijus Jonaitis   +2 more
doaj   +1 more source

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. [PDF]

PLoS ONE, 2018
Mesalamine is commonly used to treat ulcerative colitis (UC). Although mesalamine acts topically, in vitro data suggest that intracellular transport is required for its beneficial effect.
Christopher J Moran, Hailiang Huang, Manuel Rivas, Jess L Kaplan, Mark J Daly, Harland S Winter   +5 more
doaj   +1 more source

Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis. [PDF]

J Pers Med
Pagnini C, Antonelli E, Scrivo B, Cappello M, Soncini M, Vassallo R, Mocci G, Di Paolo MC, On Behalf Of Aigo Ibd Commission.   +8 more
europepmc   +3 more sources

Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment

Frontiers in Pharmacology, 2021
Mesalamine has been well used in the improvement of ulcerative colitis (UC) in clinics, however, the underlying mechanisms were not well illustrated. To explore its efficacy from the perspective of gut microbiota and related metabolites, we employed 16S ...
Liang Dai, Yingjue Tang, Wenjun Zhou, Yanqi Dang, Qiaoli Sun, Zhipeng Tang, Mingzhe Zhu, Mingzhe Zhu, Guang Ji   +8 more
doaj   +1 more source

Oxidation of Mesalamine under Phenoloxidase- or Peroxidase-like Enzyme Catalysis

Molecules, 2023
Mesalamine, also called 5-ASA (5-aminosalicylic acid), is a largely used anti-inflammatory agent and is a main choice to treat Ulcerative Colitis. This report is aimed to investigate enzymatic processes involved in the oxidation of mesalamine to better ...
Rimaz El Zein, Pompilia Ispas-Szabo, Maziar Jafari, Mohamed Siaj, Mircea Alexandru Mateescu   +4 more
doaj   +1 more source

Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis

Case Reports in Gastroenterology, 2011
Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis (UC) because of its efficacy and fewer side effects. However, earlier study showed that mesalamine occasionally causes diarrhea.
Yuichi Shimodate, Kunihiro Takanashi, Eriko Waga, Tomoki Fujita, Shinichi Katsuki, Masafumi Nomura   +5 more
doaj   +1 more source

Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon ReceptorSummary

Cellular and Molecular Gastroenterology and Hepatology, 2017
Background & Aims: Mesalamine is a first-line drug for treatment of inflammatory bowel diseases (IBD). However, its mechanisms are not fully understood. CD4+ Foxp3+ regulatory T cells (Tregs) play a potential role in suppressing IBD.
Kyoko Oh-oka, Yuko Kojima, Koichiro Uchida, Kimiko Yoda, Kayoko Ishimaru, Shotaro Nakajima, Jun Hemmi, Hiroshi Kano, Yoshiaki Fujii-Kuriyama, Ryohei Katoh, Hiroyuki Ito, Atsuhito Nakao   +11 more
doaj   +1 more source

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study [PDF]

Intestinal Research, 2016
Background/AimsThe therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients.
Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi   +4 more
doaj   +1 more source

Recent advances in mesalamine colonic delivery systems

Future Journal of Pharmaceutical Sciences, 2020
Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing ...
Mohammad F. Bayan, Rana F. Bayan
doaj   +1 more source